Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
A newly published paper in Clinical Cancer Research found that when patients successfully treated with fixed-duration ibrutinib-venetoclax developed progressive disease, they had no acquired resistance mutations in BTK, BCL2, or PLCG2.
Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).
Join Dr. Koffman as he and Dr. Adrian Wiestner discuss A New Oral BTK Protein Degrader: A novel drug designed to overcome resistance to BTK Inhibitors.
Bruton tyrosine kinase (BTK) degraders are a new therapeutic area that might be able to overcome mutations that cause resistance to BTK inhibitors.
In this study published in the New England Journal of Medicine in February 2022, a large group of researchers performed genetic testing in patients before treatment and in patients that relapsed or failed treatment with the noncovalent BTKi, Pirtobrutinib. These tests allowed the researchers to discover many other genetic mutations in CLL / SLL cells.
At the virtual American Society of Hematology Annual Meeting and Exposition or ASH 2020, Dr. Alexey Danilov of City of Hope was interviewed by CLL Society’s Steve Bloom on his important preclinical research to address one of the significant unmet needs in CLL / SLL/ patients: resistant to venetoclax and/or ibrutinib.
By Larry Marion Part one of two. Part two will be continued next week. Resistance is the scariest word in the English language for chronic lymphocytic leukemia patients. Novel agents such
At the ASH (American Society of Hematology) annual meeting in 2017 held in Atlanta, GA, I had the opportunity to interview my friend, Professor Michael Hallek from the University of Cologne,
At ASH 2016 Dr. George Follows of Cambridge, England discusses our evolving understanding of life after ibrutinib for those of us with CLL. Richter’s transformation tends to occur early on and may be a reflection of the heavy treatment many patients had received before starting ibrutinib in the early trials and is not part of this interview.
One click to our most popular content.
